News Oct 19, 2017 | Original Story by Kevin Jiang for Harvard Medical School.
An image of a breast tumor and its local environment. Tumor cells display in cyan, macrophages in red, collagen fibers in green. Credit: National Cancer Institute.
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.
The findings, published online ahead of print on Oct. 12, show that the presence of ammonia accelerates proliferation of cultured breast cancer cells, while suppressing ammonia metabolism can stunt tumor growth in mice.
The insights shed light on the biological role of ammonia in cancer and may inform the design of new therapeutic strategies to slow tumor growth, the researchers said.
“Classically, ammonia was thought to be metabolic waste that must be cleared due to its high toxicity,” said senior study author Marcia Haigis, associate professor of cell biology at HMS. “We found that not only was ammonia not toxic for breast cancer cells, it could be used to feed tumors by serving as a source for the building blocks that tumors need to grow.”
Rapidly growing cells, particularly cancer cells, consume nutrients voraciously and generate excess metabolic waste. One such byproduct, ammonia, is normally transported in blood vessels to the liver, where it is converted into less toxic substances and excreted from the body as urea. Tumors, however, have few blood vessels, and as a result, ammonia accumulates in the tumor’s local environment at concentrations that would be toxic for many cells.
To investigate how tumors cope with high levels of ammonia, Haigis and her colleagues used a technique to label the nitrogen on glutamine. When glutamine is broken down during cell metabolism, ammonia containing labeled nitrogen is released as a byproduct.
Tracing the fate of this marked ammonia, the researchers analyzed more than 200 different cellular metabolites in breast cancer cells and in human tumors transplanted into mice.
They found cancer cells recycled ammonia with high efficiency, incorporating it into numerous components—primarily the amino acid glutamate, a fundamental building block for proteins, as well as its derivatives. Around 20 percent of the cellular glutamate pool contained recycled nitrogen.
Higher concentrations of ammonia appeared to accelerate the growth of lab-grown breast cancer cells. Ammonia-exposed cells doubled up to seven hours faster than cells grown without ammonia. In 3-D cultures—a technique that allows cells to divide in all directions as they do inside the body—ammonia exposure increased the number of cells and surface area of cell clusters by up to 50 percent compared with cells grown without ammonia.
Ammonia also accelerated tumor growth and proliferation in mice with transplanted human breast cancer. When the team blocked the activity of glutamate dehydrogenase (GDH)—an enzyme that specifically assimilates ammonia to carry out its function—tumor growth slowed significantly compared to tumors with intact GDH activity.
“We found that repressing ammonia metabolism stunts tumor growth in mice,” said Jessica Spinelli, a graduate student in the Haigis lab and first author on the study. “Therefore, inhibition of ammonia assimilation or ammonia production may be rational strategies for therapy design.”
The team’s findings indicate that the biological role of ammonia should be reevaluated, laying the foundation for the investigation of new approaches to block tumor growth by depriving tumors of essential nutrients. The researchers are now exploring the therapeutic implications of ammonia metabolism in cancer.
This article has been republished from materials provided by Harvard Medical School. Note: material may have been edited for length and content. For further information, please contact the cited source.
Spinelli JB, Yoon H, Ringel AE, Jeanfavre S, Clish CB, Haigis MC. Metabolic recycling of ammonia via glutamate dehydrogenase supports breast cancer biomass. Science. 2017 Oct 12. pii: eaam9305. doi: 10.1126/science.aam9305. [Epub ahead of print] PubMed PMID: 29025995.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Improved Capture of Free-Floating Cancer Cells, Cast-Off from TumorsNews
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center and University of Wisconsin-Madison have demonstrated improved methods of capturing free-floating cancer cells that are cast-off from tumors, and circulating in the blood.READ MORE
Biomarkers to Personalize Treatment of Head and Neck CancerNews
Researchers at A.C. Camargo Cancer Center in Brazil have found markers in the blood of head and neck cancer patients that can help identify cases that are likely to evolve to metastasis or develop local relapse after treatment.READ MORE